Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Umbert

Showing results (151-160 of 167) with videos related to

Pageof 17
Sort By:
The Journal of Clinical Investigation|June 21, 2021
Cytomegalovirus mediates expansion of IL-15-responsive innate-memory cells with SIV killing functionGema Méndez-Lagares, Ning Chin, W L William Chang, et al.
European Journal of Cancer (Oxford, England : 1990)|May 3, 2017
Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancerA Dezellus, P Barriere, M Campone, et al.
Plos One|September 28, 2017
Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-BMiriam Rosás-Umbert, Beatriz Mothe, Marc Noguera-Julian, et al.
Eclinicalmedicine|July 18, 2019
Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study)Beatriz Mothe, Christian Manzardo, Alvaro Sanchez-Bernabeu, et al.
Clinical and Experimental Immunology|April 10, 2026
Immunological Dysfunction Associated with SARS-CoV-2 Persistence in Immunocompromised PatientsIda M Johannsen, Line K Vibholm, Giacomo S Frattari, et al.
Eclinicalmedicine|January 21, 2020
Corrigendum to 'Therapeutic vaccination refocuses T-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study)' EClinicalMedicine 11 (2019) 65-80Beatriz Mothe, Christian Manzardo, Alvaro Sanchez-Bernabeu, et al.
Nature Communications|October 30, 2022
Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8<sup>+</sup> T cell immunityMiriam Rosás-Umbert, Jesper D Gunst, Marie H Pahus, et al.
Nature Medicine|October 27, 2022
Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trialLucia Bailón, Anuska Llano, Samandhy Cedeño, et al.
Pharmacology Research & Perspectives|January 11, 2024
A systematic review on experimental studies about patient adherence to treatmentFrans Folkvord, Ana Roca-Umbert Würth, Karlijn van Houten, et al.
Ebiomedicine|March 24, 2022
Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcomeBruna Oriol-Tordera, Anna Esteve-Codina, María Berdasco, et al.
Pageof 17

Showing results (151-160 of 167) with videos related to

Sort By:
Pageof 17
The Journal of Clinical Investigation|June 21, 2021
Cytomegalovirus mediates expansion of IL-15-responsive innate-memory cells with SIV killing functionGema Méndez-Lagares, Ning Chin, W L William Chang, et al.
European Journal of Cancer (Oxford, England : 1990)|May 3, 2017
Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancerA Dezellus, P Barriere, M Campone, et al.
Plos One|September 28, 2017
Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-BMiriam Rosás-Umbert, Beatriz Mothe, Marc Noguera-Julian, et al.
Eclinicalmedicine|July 18, 2019
Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study)Beatriz Mothe, Christian Manzardo, Alvaro Sanchez-Bernabeu, et al.
Clinical and Experimental Immunology|April 10, 2026
Immunological Dysfunction Associated with SARS-CoV-2 Persistence in Immunocompromised PatientsIda M Johannsen, Line K Vibholm, Giacomo S Frattari, et al.
Eclinicalmedicine|January 21, 2020
Corrigendum to 'Therapeutic vaccination refocuses T-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study)' EClinicalMedicine 11 (2019) 65-80Beatriz Mothe, Christian Manzardo, Alvaro Sanchez-Bernabeu, et al.
Nature Communications|October 30, 2022
Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8<sup>+</sup> T cell immunityMiriam Rosás-Umbert, Jesper D Gunst, Marie H Pahus, et al.
Nature Medicine|October 27, 2022
Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trialLucia Bailón, Anuska Llano, Samandhy Cedeño, et al.
Pharmacology Research & Perspectives|January 11, 2024
A systematic review on experimental studies about patient adherence to treatmentFrans Folkvord, Ana Roca-Umbert Würth, Karlijn van Houten, et al.
Ebiomedicine|March 24, 2022
Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcomeBruna Oriol-Tordera, Anna Esteve-Codina, María Berdasco, et al.
Pageof 17